The forthcoming implementation of the European Clinical Trial Regulation (Regulation (EU) No. 536/2014), which is expected to facilitate the conduct of clinical trials across the European Union, will require National Authorities to create the best conditions for the implementation of the new Regulation through national guidelines, so that sponsors may reconsider Europe as a prime location for planning clinical trials. During a meeting titled "Innovation in Clinical Research", an expert panel discussed potential local advances fostering competitiveness of European clinical research with representatives of the pharmaceutical industry, patient organisations and Italian regulatory agency in view of the forthcoming implementation of (EU) No. 536/2014 on clinical trials of medicinal products. In this article we summarise the findings of the meeting, describe features characterising clinical research patterns and offer some suggestions on the possible involvement of all stakeholders in order to foster research innovation and allow the timely access to novel medicines for patients.
A harmonized and efficient clinical research environment would benefit patients and enhance European competitiveness / A. Amato, E. Aringhieri, S. Boccia, F. Buccella, B. Gorini, D. Gramaglia, R. Masetti, P. Rossi, P.G. Pelicci. - In: ANNALI DELL'ISTITUTO SUPERIORE DI SANITÀ. - ISSN 0021-2571. - 53:2(2017), pp. 104-107. [10.4415/ANN_17_02_05]
A harmonized and efficient clinical research environment would benefit patients and enhance European competitiveness
P. RossiPenultimo
;P.G. PelicciUltimo
2017
Abstract
The forthcoming implementation of the European Clinical Trial Regulation (Regulation (EU) No. 536/2014), which is expected to facilitate the conduct of clinical trials across the European Union, will require National Authorities to create the best conditions for the implementation of the new Regulation through national guidelines, so that sponsors may reconsider Europe as a prime location for planning clinical trials. During a meeting titled "Innovation in Clinical Research", an expert panel discussed potential local advances fostering competitiveness of European clinical research with representatives of the pharmaceutical industry, patient organisations and Italian regulatory agency in view of the forthcoming implementation of (EU) No. 536/2014 on clinical trials of medicinal products. In this article we summarise the findings of the meeting, describe features characterising clinical research patterns and offer some suggestions on the possible involvement of all stakeholders in order to foster research innovation and allow the timely access to novel medicines for patients.File | Dimensione | Formato | |
---|---|---|---|
A harmonized and efficient .pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
61.91 kB
Formato
Adobe PDF
|
61.91 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.